EMA Withdrawn: BroPair Spiromax (salmeterol xinafoate;fluticasone propionate) — Teva B.V.

View source ↗

Summary

EMA has withdrawn BroPair Spiromax, a salmeterol xinafoate and fluticasone propionate inhaler for asthma. The withdrawal decision was made on 01/04/2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• BroPair Spiromax (salmeterol xinafoate; fluticasone propionate)

Snippet

Status: Withdrawn. Therapeutic area: Asthma. MAH: Teva B.V.. Decision date: 01/04/2025